Why the study?
Cardiac magnetic resonance precisely monitors disease activity to quantify response to therapeutics, warranting a critical appraisal of its biomarkers as surrogate endpoints in prospective trials for myocardial diseases.
This review highlights the utility of cardiac magnetic resonance biomarkers as surrogate endpoints to monitor disease activity and quantify therapeutic response in myocardial diseases.
Answers are grounded in this paper and cite their sources.
May improve therapeutic monitoring in myocardial diseases; leaves open validation of CMR biomarkers as surrogate endpoints in trials.
Cardiac magnetic resonance offers multiple facets in the diagnosis, risk stratification, and management of patients with myocardial diseases. Particularly, its feature to precisely monitor disease activity lends itself to quantify response to novel therapeutics. This review critically appraises the value of cardiac magnetic resonance imaging biomarkers as surrogate endpoints for prospective clinical trials. The primary focus is to comprehensively outline the value of established cardiac magnetic resonance parameters in myocardial diseases. These include heart failure, cardiac amyloidosis, iron overload cardiomyopathy, hypertrophic cardiomyopathy, cardio-oncology, and inflammatory cardiomyopathies like myocarditis and sarcoidosis.
No takes yet. Share an insight, caveat, or question.
Benz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: